Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parsaclisib - Incyte Corporation

Next Previous
X
Search
Drug Profile

Parsaclisib - Incyte Corporation

Alternative Names: IBI-376; INCB-050465; INCB-50465

Latest Information Update: 26 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; Innovent Biologics; Mayo Clinic; National Cancer Institute (USA)
  • Class Antianaemics; Antihaemorrhagics; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Ketones; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Marginal zone B-cell lymphoma; Autoimmune haemolytic anaemia; Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Follicular lymphoma
  • Phase III Myelofibrosis
  • Phase II B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
  • Preclinical Systemic lupus erythematosus
  • Discontinued Autoimmune haemolytic anaemia; Sjogren's syndrome

Most Recent Events

  • 07 Jun 2024 Incyte Corporation completes a CITADEL-203 phase II trial in Follicular lymphoma (Second-line therapy or greater) in USA, Australia, Canada, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden and United Kingdom (NCT03126019) (EudraCT2017-001624-22)
  • 30 Apr 2024 Incyte Corporation completes a phase II clinical trials in Mantle-cell lymphoma (Second-line therapy or greater) in US, Belgium, Czech Republic, Denmark, France, Germany, Israel, Italy, Poland, Spain and the UK (PO) (NCT03235544)
  • 29 Apr 2024 Incyte Corporation terminates a phase III PATHWAY trial for Autoimmune haemolytic anaemia in United Kingdom, Spain, Spain, Poland, Netherlands, Japan, Israel, Germany, Belgium, Canada, USA, Italy, Austria and France(PO), due to business decision (NCT05073458)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top